| Code | CSB-RA023984MB9HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is a research-grade biosimilar to EU-101, designed to specifically target TNFRSF9 (Tumor Necrosis Factor Receptor Superfamily Member 9), also known as 4-1BB or CD137. TNFRSF9 is an inducible costimulatory receptor expressed primarily on activated T cells, NK cells, and other immune cell populations. Upon binding to its ligand 4-1BBL, TNFRSF9 delivers critical signals that enhance T cell proliferation, survival, and effector function, while also promoting cytotoxic activity in NK cells. This receptor plays a pivotal role in immune regulation and has emerged as a significant target in cancer immunotherapy research, as its activation can enhance anti-tumor immune responses and improve immunological memory.
EU-101 is an investigational anti-CD137 antibody that aims to enhance the proliferation, survival and function of T cells (especially cytotoxic T cells) and NK cells by activating the CD137 signaling pathway, thereby strengthening the anti-tumor immune response. This biosimilar provides researchers with a valuable tool for investigating immune checkpoint biology, studying T cell activation mechanisms, and exploring novel immunotherapeutic strategies in oncology and autoimmune disease models. The antibody enables detailed examination of TNFRSF9-mediated immune responses across various experimental systems.
There are currently no reviews for this product.